The Daily Biotech Pulse: GlaxoSmithKline And Halozyme Go Shopping, Mylan's Insulin Glargine Recall, Turning Point Shares Lung Cancer Data And More
Benzinga
APRIL 13, 2022
Halozyme Buys Specialty Product Company Antares In $960M Deal. Halozyme Therapeutics Inc (NASDAQ: HALO ) will acquire Antares Pharma Inc (NASDAQ: ATRS ) for $5.60 GlaxoSmithKline Scoops Up Rare Cancer-Focused Sierra Oncology In $1.9B Stocks In Focus. per share , valuing Antares at approximately $960 million.
Let's personalize your content